All Stories

  1. Top-down guidance of attention to food cues is enhanced in individuals with overweight/obesity and predicts change in weight at one-year follow up
  2. Predicting treatment response to antidepressant medication using early changes in emotional processing
  3. Associations Between Core Symptoms of Attention Deficit Hyperactivity Disorder and Both Binge and Restrictive Eating
  4. The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial
  5. Multidisciplinary approaches to the study of eating disorders and obesity: Recent progress in research and development and future prospects
  6. The 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers
  7. Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies
  8. Attention Deficit Hyperactivity Disorder (ADHD) and disordered eating behaviour: A systematic review and a framework for future research
  9. The relationship between attention deficit hyperactivity disorder (ADHD) and disordered eating
  10. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate
  11. Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies
  12. Test–retest reliability and effects of repeated testing and satiety on performance of an Emotional Test Battery
  13. Effects of awareness that food intake is being measured by a universal eating monitor on the consumption of a pasta lunch and a cookie snack in healthy female volunteers
  14. Investigating virtual reality navigation in amnestic mild cognitive impairment using fMRI
  15. Satiation attenuates BOLD activity in brain regions involved in reward and increases activity in dorsolateral prefrontal cortex: an fMRI study in healthy volunteers
  16. Alterations in working memory networks in amnestic mild cognitive impairment
  17. Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers
  18. Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia
  19. Monitoring eating behaviour in the laboratory. Do we need to do it covertly?
  20. The effects of ketamine and risperidone on eye movement control in healthy volunteers
  21. S.1.4 - DRUGS FOR OBESITY
  22. G.9 - EFFECT OF META-CHLOROPHENYLPIPERAZINE (MCPP) ON APPETITE, SATIETY AND FMRI BOLD SIGNAL IN HEALTHY VOLUNTEERS
  23. Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate
  24. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy
  25. Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans
  26. Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants
  27. The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO2-induced anxiety
  28. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study
  29. Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic
  30. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy
  31. Special issue on CNS experimental medicine
  32. Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)
  33. Validation of experimental medicine methods in psychiatry: The P1vital approach and experience
  34. Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety
  35. P.4.010 A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy
  36. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models
  37. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women
  38. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives
  39. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives
  40. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines
  41. Anti-obesity Drugs: From Animal Models to Clinical Efficacy
  42. Synthesis and biological evaluation of novel hexahydro-pyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT2C receptor agonists
  43. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse
  44. Pyrrolo(iso)quinoline derivatives as 5-HT2C receptor agonists
  45. Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists
  46. Tonic regulation of satiety by 5-HT1B receptors in the mouse: converging evidence from behavioural and c-fos immunoreactivity studies?
  47. Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice
  48. Indoline derivatives as 5-HT 2C receptor agonists
  49. mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes
  50. Company founders: voices of experience
  51. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease
  52. Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation
  53. Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia
  54. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats
  55. 5-HT1Breceptor knockout mice show a compensatory reduction in 5-HT2Creceptor function
  56. 5-HT 1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin 1B agonist CP-94,253
  57. Serotonin 2C receptor agonists and the behavioural satiety sequence in mice
  58. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors
  59. Case Series: Amantadine Open-Label Treatment of Impulsive and Aggressive Behavior in Hospitalized Children With Developmental Disabilities
  60. Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder
  61. Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat
  62. Comparative effects of continuous infusion ofmCPP, Ro 60-0175 andd-fenfluramine on food intake, water intake, body weight and locomotor activity in rats
  63. Measurement of Anxiety in Transgenic Mice
  64. 5-HT2C receptor modulation and the treatment of obesity
  65. Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice
  66. Utility of ethological analysis to overcome locomotor confounds in elevated maze models of anxiety
  67. Blockade of pre-and post-synaptic 5-HT 1A receptors does not modify the effect of fluoxetine or 5-hydroxytryptophan on ethanol and food intake in rats
  68. WAY100635 and latent inhibition in the rat: selective effects at preexposure
  69. Behavioural and pharmacological characterisation of the canopy stretched attend posture test as a model of anxiety in mice and rats
  70. Devazepide Attenuates dl-Fenfluramine-Induced Suppression of Gastric Emptying but Not Food Intake in the 17 h Food-Deprived Rat
  71. Effects of 5-HT 1A receptor agonists, partial agonists and a silent antagonist on the performance of the conditioned emotional response test in the rat
  72. Lack of Interaction Between Devazepide and 8-OH-DPAT-Induced Hyperphagia in the Rat
  73. Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory
  74. Behavioural evidence thatd-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype
  75. Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists
  76. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist
  77. Multiple Serotonin Receptors: Opportunities for New Treatments for Obesity?
  78. Benefits of ethological analysis of behaviour
  79. Analysis of glutamate in striatal microdialysates using capillary electrophoresis and laser-induced fluorescence detection
  80. Comparisons between the effects of 5-HT and dl-fenfluramine on food intake and gastric emptying in the rat
  81. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190
  82. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze
  83. Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635
  84. Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety
  85. Effects of the selective 5-HT1A receptor antagonist WAY100135 and its enantiomers on 8-OH-DPAT-induced hyperglycaemia in conscious rats
  86. In vivo characterization of the putative 5-HT1A receptor antagonist SDZ 216,525 using two models of somatodendritic 5-HT1A receptor function
  87. The angiotensin converting enzyme inhibitors captopril and enalapril inhibit apomorphine-induced oral stereotypy in the rat
  88. An examination of the behavioural specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial satiety sequence in rats
  89. Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents
  90. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice
  91. Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study
  92. Na+ channels
  93. The effects of 5-HT and dl-fenfluramine on gastric emptying and food intake in fasted rats
  94. Effects of the putative 5-HT1A receptor antagonist NAN-190 on free feeding and on feeding induced by the 5-HT1A receptor agonist 8-OH-DPAT in the rat
  95. Drinking induced by subcutaneous injection of angiotensin II in the rat is blocked by the selective AT1 receptor antagonist DuP 753 but not by the selective AT2 receptor antagonist WL 19
  96. L-683,877: Pharmacological profile of a novel 5-HT3 receptor antagonist
  97. Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats
  98. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260
  99. Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding
  100. Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey
  101. Cholecystokinin and anxiety
  102. The anti-emetic action of the novel 5-HT3 receptor antagonist L-683,877 in the ferret
  103. Pharmacological characterization of the behavioral syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT
  104. Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329
  105. Fluoxetine reduces food intake by a cholecystokinin-independent mechanism
  106. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat
  107. The role of CCK, caerulein, and CCK antagonists in nociception
  108. Blockade of apomorphine-induced yawning in rats by the dopamine autoreceptor antagonist (+)-AJ 76
  109. Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors
  110. MK-212 increases rat plasma ACTH concentration by activation of the 5-HT1C receptor subtype
  111. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors
  112. Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy
  113. Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists
  114. Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329
  115. The role of 5-HTB receptors in the paraventricular nucleus of the hypothalamus in the control of feeding
  116. Evidence that blockade of post-synaptic 5-HT1 receptors elicits feeding in satiated rats
  117. Role of dopamine D-1 and D-2 receptor subtypes in mediating dopamine agonist effects on food consumption in rats
  118. The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation
  119. Antinociceptive effects of novel, selective tachykinin receptor antagonists in thermal and chemical analgesia tests
  120. Behavioural evidence for CNS tachykinin-cholinergic interactions
  121. Pharmacological characterization of central tachykinin: 5-HT interactions
  122. The role of NK-3 and NK-4 receptors in the mediation of reciprocal hindlimb scratching induced by tachykinin receptor agonists
  123. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats
  124. 8-OH-DPAT elicits feeding and not chewing: evidence from liquid diet studies and a diet choice test
  125. CCK-A receptors in the rat interpeduncular nucleus: evidence for a presynaptic location
  126. Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A receptors
  127. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718
  128. Relationship of increased food intake and plasma ACTH levels to 5-HT1A receptor activation in rats
  129. The 5-HT1A agonist 8-OH-DPAT increases consumption of palatable wet mash and liquid diets in the rat
  130. Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra
  131. Effects of the novel anxiolytics gepirone, buspirone and ipsapirone on free feeding and on feeding induced by 8-OH-DPAT
  132. Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse
  133. 5-HT1B agonists induce anorexia at a postsynaptic site
  134. Classification and function of CCK receptors
  135. Single administration of 5-HT1A agonists decreases 5-HT1A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action
  136. Experimental Psychopharmacology
  137. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression
  138. Effects of Drugs on Spontaneous Motor Activity
  139. The 5-HT1A agonists 8-OH-DPAT, buspirone and ipsapirone attenuate stress-induced anorexia in rats
  140. Monitoring 5HT Metabolism in the Brain of the Freely Moving Rat
  141. Neurochemical and behavioural evidence for mediation of the hyperphagic action of 8-OH-DPAT by 5-HT cell body autoreceptors
  142. Para-chlorophenylalanine prevents feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)
  143. Pustative anxiolytics 8-OH-DPAT, buspirone and TVX Q 7821 are agonists at 5-HT1A autoreceptors in the raphé nuclei
  144. Bilateral lesions of the striatum induced with 6-hydroxydopamine abolish apomorphine-induced yawning in rats
  145. Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)
  146. Pharmacological and biochemical analysis of feeding behaviour
  147. Preface
  148. Behavioural evidence for the existence of dopamine autoreceptors
  149. Local application of β-phenylethylamine to the caudate nucleus of the rat elicits locomotor stimulation
  150. Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat
  151. Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat
  152. Environmental experience produces qualitative changes in the stimulant effects of ?-phenylethylamine in rats
  153. Potentiation of total horizontal activity and ambulation in rats treated with combinations of β-phenylethylamine and naloxone
  154. Locomotor Stimulant Effect of β-Phenylethylamine-Naloxone Mixtures
  155. Effects of Tryptamine and 5-Hydroxytryptamine on Food Intake in the Rat
  156. Differential aversive stimulus properties of ?-phenylethylamine and of d-amphetamine
  157. Effects of piribedil and of d-amphetamine on locomotor activity in immature rats
  158. Hypodipsia, stereotypy and hyperactivity induced by β-phenylethylamine in the water-deprived rat
  159. Deuterium substitution enhances the effects of β-phenylethylamine on spontaneous motor activity in the rat
  160. Potentiation of the behavioural effects of the antidepressant phenelzine by deuterium substitution
  161. Dopaminergic involvement in the control of drinking behaviour: A brief review
  162. Pharmacology of β-phenylethylamine-induced seizures in mice
  163. Piribedil: Behavioural, neurochemical and clinical profile of a dopamine agonist
  164. Putative PEA receptors?
  165. Alterations in trace amine and trace acid concentrations in isolated aggressive mice
  166. The role of catecholamines, 5-hydroxytryptamine and m-tyramine in the behavioural effects of m-tyrosine in the rat
  167. A PHARMACOLOGICAL ANALYSIS OF THE HYPERACTIVITY SYNDROME INDUCED BY β-PHENYLETHYLAMINE IN THE MOUSE
  168. Variation in response to stimulation of central 5-hydroxytryptamine mechanisms in two strains of albino rat
  169. Dopamine agonist-induced restoration of drinking in response to hypertonie saline in adipsic dopamine denervated rats
  170. An observational analysis of the behavioural effects of β-Phenylethylamine in isolated and grouped mice
  171. Behavioural and neurochemical effects of meta-tyrosine in the rat
  172. Biphasic behavioural stimulation induced by a monoamine oxidase-inhibiting antidepressant
  173. Suppression of drinking and induction of sedation by a dopamine agonists is blocked by small doses of spiperone
  174. Behavioural effects of acute and chronic β-phenylethylamine administration in the rat: Evidence for the involvement of 5-hydroxytryptamine
  175. Single or repeated administration of small doses of apomorphine on water intake and activity in water-deprived rats
  176. Effects of acute or chronic administration of low doses of a dopamine agonist on drinking and locomotor activity in the rat
  177. The effects of acute and chronic administration of β-phenylethylamine on food intake and body weight in rats
  178. Effects of et 495 (piribedil) on water intake in the rat: Evidence for a dopaminergic involvement in thirst
  179. Effects of Drugs on Spontaneous Motor Activity